CY1112924T1 - Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγης - Google Patents
Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγηςInfo
- Publication number
- CY1112924T1 CY1112924T1 CY20121100593T CY121100593T CY1112924T1 CY 1112924 T1 CY1112924 T1 CY 1112924T1 CY 20121100593 T CY20121100593 T CY 20121100593T CY 121100593 T CY121100593 T CY 121100593T CY 1112924 T1 CY1112924 T1 CY 1112924T1
- Authority
- CY
- Cyprus
- Prior art keywords
- disruptions
- jnk
- cell signaling
- present
- inhibitors
- Prior art date
Links
- 230000005754 cellular signaling Effects 0.000 title 1
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 abstract 2
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 abstract 2
- 239000003909 protein kinase inhibitor Substances 0.000 abstract 2
- 239000012825 JNK inhibitor Substances 0.000 abstract 1
- 108091006116 chimeric peptides Proteins 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000007310 pathophysiology Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16371—Demonstrated in vivo effect
Abstract
Η παρούσα εφεύρεση αφορά σε αναστολείς πρωτεϊνικής κινάσης και ειδικότερα σε αναστολείς της πρωτεϊνικής κινάσης c-Jun αμινοτελική κινάση. Επιπλέον η παρούσα εφεύρεση παρέχει ακολουθίες αναστολέων JNΚ, χιμαιρικά πεπτίδια, νουκλεϊνικά οξέα που κωδικεύουν τα ίδια καθώς και φαρμακευτικές συνθέσεις για τη θεραπεία που σχετίζεται με παθοφυσιολογίες με σηματοδότηση JΝΚ.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2005/009782 WO2007031098A1 (en) | 2005-09-12 | 2005-09-12 | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
EP06792004A EP1928903B1 (en) | 2005-09-12 | 2006-09-12 | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1112924T1 true CY1112924T1 (el) | 2016-04-13 |
Family
ID=35686501
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100593T CY1112924T1 (el) | 2005-09-12 | 2012-07-04 | Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγης |
CY20161100290T CY1117351T1 (el) | 2005-09-12 | 2016-04-11 | Κυτταροδιαπερατοι αναστολεις πεπτιδιων της jnk-σηματοδοτικης πορειας μεταγωγης |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161100290T CY1117351T1 (el) | 2005-09-12 | 2016-04-11 | Κυτταροδιαπερατοι αναστολεις πεπτιδιων της jnk-σηματοδοτικης πορειας μεταγωγης |
Country Status (25)
Country | Link |
---|---|
US (5) | US8748395B2 (el) |
EP (3) | EP1928903B1 (el) |
JP (3) | JP5386169B2 (el) |
KR (1) | KR101305533B1 (el) |
CN (1) | CN101263157B (el) |
AU (1) | AU2006291541B2 (el) |
BR (1) | BRPI0616824B8 (el) |
CA (1) | CA2621337C (el) |
CY (2) | CY1112924T1 (el) |
DK (2) | DK2418217T3 (el) |
EA (1) | EA014330B1 (el) |
ES (2) | ES2388076T3 (el) |
HK (3) | HK1118841A1 (el) |
HR (2) | HRP20120598T1 (el) |
HU (1) | HUE029132T2 (el) |
IL (2) | IL189133A (el) |
ME (2) | ME02000B (el) |
NO (1) | NO342272B1 (el) |
PL (2) | PL2418217T4 (el) |
PT (1) | PT1928903E (el) |
RS (2) | RS52379B (el) |
SI (2) | SI2418217T1 (el) |
UA (1) | UA98101C2 (el) |
WO (2) | WO2007031098A1 (el) |
ZA (1) | ZA200800848B (el) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040082509A1 (en) | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US8183339B1 (en) | 1999-10-12 | 2012-05-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US8080517B2 (en) | 2005-09-12 | 2011-12-20 | Xigen Sa | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
CA2663545A1 (en) | 2006-09-19 | 2008-03-27 | Phylogica Limited | Neuroprotective peptide inhibitors of ap-1 signaling and uses thereof |
US8822409B2 (en) | 2007-06-20 | 2014-09-02 | Phylogica Limited | Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith |
CN102014957B (zh) | 2008-04-21 | 2014-12-10 | 奥德纳米有限公司 | 用于治疗耳部疾病和病况的耳用调配物 |
MX2010012397A (es) | 2008-05-14 | 2011-03-15 | Otonomy Inc Star | Composiciones de corticosteroides de liberacion controlada y metodos para el tratamiento de transtornos oticos. |
US8648119B2 (en) | 2008-05-23 | 2014-02-11 | Otonomy, Inc. | Controlled release immunomodulator compositions and methods for the treatment of otic disorders |
WO2009143865A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2009143864A1 (en) * | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
US8846770B2 (en) | 2008-06-18 | 2014-09-30 | Otonomy, Inc. | Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders |
US8349353B2 (en) | 2008-06-27 | 2013-01-08 | Otonomy, Inc. | Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders |
WO2010011466A2 (en) | 2008-06-27 | 2010-01-28 | Otonomy, Inc. | Controlled-release cns modulating compositions and methods for the treatment of otic disorders |
GB2461961A (en) * | 2008-07-14 | 2010-01-27 | Otonomy Inc | Sterile anti-apoptotic agent for treatment of ear diseases |
US8318817B2 (en) | 2008-07-21 | 2012-11-27 | Otonomy, Inc. | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
US8496957B2 (en) | 2008-07-21 | 2013-07-30 | Otonomy, Inc | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
WO2010011605A2 (en) | 2008-07-21 | 2010-01-28 | Otonomy, Inc. | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders |
US8784870B2 (en) | 2008-07-21 | 2014-07-22 | Otonomy, Inc. | Controlled release compositions for modulating free-radical induced damage and methods of use thereof |
US8399018B2 (en) | 2008-07-21 | 2013-03-19 | Otonomy, Inc. | Controlled release ion channel modulator compositions and methods for the treatment of otic disorders |
JP2012506436A (ja) | 2008-10-22 | 2012-03-15 | ハウス イアー インスティトゥート | 代謝型グルタミン酸受容体の調節による内耳の疾病の処置および/または予防 |
WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
WO2010113753A1 (ja) | 2009-03-30 | 2010-10-07 | 参天製薬株式会社 | JNK(c-Junアミノ末端キナーゼ)阻害ペプチドを用いた網膜疾患の予防または治療剤、網膜疾患の予防または治療方法、ならびに、その使用 |
US20120077753A1 (en) * | 2009-06-25 | 2012-03-29 | Laxman Gangwani | Jnk inhibitors for use in treating spinal muscular atrophy |
WO2011160653A1 (en) * | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
US9150618B2 (en) | 2010-10-14 | 2015-10-06 | Xigen Inflammation Ltd. | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
SG11201402347YA (en) * | 2011-11-30 | 2014-06-27 | Xigen Inflammation Ltd | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of dry eye syndrome |
WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
CN105307670A (zh) | 2013-06-26 | 2016-02-03 | 埃克西金炎症有限公司 | Jnk信号转导途径的细胞渗透肽抑制剂用于治疗多种疾病的新用途 |
WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
WO2014206426A1 (en) * | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
WO2015197098A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
MX2016002408A (es) | 2013-08-27 | 2016-10-28 | Otonomy Inc | Metodos para el tratamiento de trastornos oticos pediatricos. |
WO2015106098A1 (en) * | 2014-01-09 | 2015-07-16 | University Of South Florida | Amyloid precursor protein (app) based b-secretase inhibitor peptides, and methods of use |
CN106455579A (zh) * | 2014-04-23 | 2017-02-22 | 耳瑞思医学股份有限公司 | 用于治疗和预防耳鸣的方法和组合物 |
US20150374779A1 (en) * | 2014-06-26 | 2015-12-31 | Auris Medical Ag | Pharmacologic treatments of meniére's disease |
EP3160989A2 (en) * | 2014-06-26 | 2017-05-03 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
EP3204031A2 (en) | 2014-10-08 | 2017-08-16 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
US10190096B2 (en) | 2014-12-18 | 2019-01-29 | President And Fellows Of Harvard College | Methods for generating stem cell-derived β cells and uses thereof |
US10456475B2 (en) | 2015-02-03 | 2019-10-29 | Kennsaw State University Research and Service Foundation, Inc. | Cell penetrating protein adaptor molecules and their application in research and medicine |
US10435446B2 (en) | 2015-06-03 | 2019-10-08 | Kennesaw State University Research and Service Foundation Inc. | Cell penetrating protein adaptor molecules and their application in research and medicine |
EP3411387A4 (en) | 2016-02-03 | 2019-12-04 | Kennesaw State University Research And Services Foundation Inc. | SIGNAL MOLECULES USEFUL AS CELL PENETRATION AGENTS |
WO2018029336A1 (en) | 2016-08-12 | 2018-02-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway. |
US11040004B2 (en) | 2016-09-16 | 2021-06-22 | Otonomy, Inc. | Otic gel formulations for treating otitis externa |
US11883491B2 (en) | 2017-05-03 | 2024-01-30 | St. Jude Children's Research Hospital, Inc. | Compositions and methods for prevention and treatment of hearing loss |
IT202000011176A1 (it) | 2020-05-15 | 2021-11-15 | Univ Degli Studi Milano | Peptidi inibitori di jnk3 |
WO2022020114A2 (en) | 2020-07-10 | 2022-01-27 | Ting Therapeutics Llc | Methods for the prevention and treatment of hearing loss |
Family Cites Families (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1195304B (it) | 1981-12-22 | 1988-10-12 | Anic Spa | Metodo per la preparazione di gem-diammino derivati n-monoacilati |
US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
US4698327A (en) | 1985-04-25 | 1987-10-06 | Eli Lilly And Company | Novel glycopeptide derivatives |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
IT1190389B (it) | 1985-09-19 | 1988-02-16 | Eniricerche Spa | Esapeptidi ad attivita' ipotensiva |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5169933A (en) | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
IT1227907B (it) | 1988-12-23 | 1991-05-14 | Eniricerche S P A Milano Sclav | Procedimento per la sintesi di peptidi retro-inversi e nuovi intermediin tale procedimento |
EP0454781B1 (en) | 1989-01-23 | 1998-12-16 | Chiron Corporation | Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof |
GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
US5670617A (en) | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
US6316003B1 (en) | 1989-12-21 | 2001-11-13 | Whitehead Institute For Biomedical Research | Tat-derived transport polypeptides |
US5840313A (en) | 1990-09-27 | 1998-11-24 | Syntello Vaccine Development Kb | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus |
AU1753892A (en) | 1991-04-10 | 1992-11-17 | General Hospital Corporation, The | Mammalian gap-43 compositions and methods of use |
US5350835A (en) | 1991-11-05 | 1994-09-27 | Board Of Regents, University Of Texas | Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids |
US5994108A (en) | 1991-11-05 | 1999-11-30 | Board Of Regents, The University Of Texas System | Mutant TAR virus and transdominant tat mutants as pharmacological agents |
CA2131620A1 (en) | 1992-03-20 | 1993-09-30 | Louis C. Smith | A dna transporter system and method of use |
AU682308C (en) | 1992-04-03 | 2006-08-17 | Regents Of The University Of California, The | Self-assembling polynucleotide delivery system |
WO1994004562A1 (en) | 1992-08-13 | 1994-03-03 | The General Hospital Corporation | Mammalian gap-43 compositions and methods of use |
DE656950T1 (de) | 1992-08-21 | 1996-03-14 | Biogen Inc | Tat-derivate transport polypeptide. |
EP0667786B1 (en) | 1992-08-27 | 2004-01-21 | Deakin Research Limited | Retro-, inverso-, and retro-inverso synthetic peptide analogues |
US5545551A (en) | 1992-08-28 | 1996-08-13 | Mt. Sinai School Of Medicine Of The City University Of New York | Cloning and expression of pur protein |
ES2157225T3 (es) | 1992-10-09 | 2001-08-16 | Advanced Tissue Sciences Inc | Celulas hepaticas de reserva. |
WO1994023751A1 (de) | 1993-04-14 | 1994-10-27 | Boehringer Mannheim Gmbh | Nukleinsäure-transferpeptide und deren verwendung zur einschleusung von nukleinsäuren in eukaryontische zellen |
CA2153480A1 (en) | 1993-11-12 | 1995-06-01 | Kenichi Matsubara | Gene signature |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US5807746A (en) | 1994-06-13 | 1998-09-15 | Vanderbilt University | Method for importing biologically active molecules into cells |
WO1996034093A1 (en) | 1995-04-25 | 1996-10-31 | Baxter International Inc. | Composition containing collagenase and chymopapain for isolating hepatocytes and pancreatic islet cells |
BR9610058A (pt) | 1995-07-28 | 1999-07-27 | Marie Curie Cancer Care | Uso de vp22 ou uma porção ativa fragmento ou homólogo do mesmo proteína de transporte ácido nucleíco vetor de expressão célula hospedeira de mamíferos ou microbiana e processos para transportar uma proteína ou peptídeo desejado para uma população de marcaç o de células e para transportar uma molécula desejada em uma população de células |
WO1997010836A1 (en) | 1995-09-21 | 1997-03-27 | Innapharma, Inc. | Peptides and peptidomimetics inhibiting the oncogenic action of p21 ras |
IE80466B1 (en) | 1995-11-10 | 1998-07-29 | Elan Corp Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
US5877282A (en) | 1996-09-20 | 1999-03-02 | Bristol-Myers Squibb Company | Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof |
US6187817B1 (en) | 1996-10-03 | 2001-02-13 | Southern Illinois University School Of Medicine | Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds |
US6361938B1 (en) | 1996-11-08 | 2002-03-26 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
AU7410998A (en) | 1996-11-26 | 1998-06-22 | Johns Hopkins University, The | Ligand detection system and methods of use thereof |
US5989814A (en) | 1997-04-01 | 1999-11-23 | Reagents Of The University Of California | Screening methods in eucaryotic cells |
US5880261A (en) | 1997-04-03 | 1999-03-09 | Waeber; Gerard | Transcription factor Islet-Brain 1 (IB1) |
AU6972798A (en) | 1997-04-18 | 1998-11-13 | University Of Medicine And Dentistry Of New Jersey | Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog |
US6043083A (en) | 1997-04-28 | 2000-03-28 | Davis; Roger J. | Inhibitors of the JNK signal transduction pathway and methods of use |
NZ501110A (en) | 1997-05-15 | 2001-10-26 | Elan Corp Plc | Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related drug delivery methods |
US20040152084A1 (en) | 2003-01-31 | 2004-08-05 | Slattum Paul M. | Compounds and processes for single-pot attachment of a label to nucleic acid |
CN1263473A (zh) | 1997-05-21 | 2000-08-16 | 利兰·斯坦福青年大学托管委员会 | 增加跨生物膜转运的组合物和方法 |
FR2767323B1 (fr) | 1997-08-12 | 2001-01-05 | Synt Em | Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives |
EP0897002A3 (en) | 1997-08-14 | 2001-10-04 | Smithkline Beecham Plc | U62317, a protein having a JNK-binding domain |
AU9402898A (en) | 1997-09-26 | 1999-04-23 | Washington University | Cell death agonists |
US6420031B1 (en) | 1997-11-03 | 2002-07-16 | The Trustees Of Princeton University | Highly transparent non-metallic cathodes |
HUP0100348A3 (en) | 1997-10-20 | 2002-12-28 | Hoffmann La Roche | Bicycles containing a six menbered ring with one or two nitrogen atoms, process for their preparation, use of them, pharmaceutical compositions containing the same and intermediates |
US6270956B1 (en) | 1997-12-11 | 2001-08-07 | The Salk Institute For Biological Studies | Transcriptional coactivator that interacts with Tat protein and regulates its binding to TAR RNA, methods for modulating Tat transactivation, and uses therefor |
EP0947524A1 (en) | 1998-03-30 | 1999-10-06 | Upither B.V. | Novel peptides for the treatment of autoimmune diseases |
US6248558B1 (en) | 1998-03-31 | 2001-06-19 | Vanderbilt University | Sequence and method for genetic engineering of proteins with cell membrane translocating activity |
EP1082310A4 (en) | 1998-04-29 | 2001-09-12 | Univ Georgetown | METHODS RELATING TO THE IDENTIFICATION AND USE OF COMPOUNDS THAT BIND TO HLA MOLECULES AS AGONISTS OR ANTAGONISTS TO HLA |
CA2327354A1 (en) | 1998-05-13 | 1999-11-18 | Incyte Pharmaceuticals, Inc. | Human apoptosis associated proteins |
US6811992B1 (en) | 1998-05-14 | 2004-11-02 | Ya Fang Liu | Method for identifying MLK inhibitors for the treatment of neurological conditions |
WO1999058561A1 (fr) | 1998-05-14 | 1999-11-18 | Pasteur Merieux Serums & Vaccins | Mimotopes du virus de l'hepatite c |
CA2331384A1 (en) | 1998-06-18 | 1999-12-23 | Dnavec Research Inc. | Nucleic acid transfer phage |
US6589503B1 (en) | 1998-06-20 | 2003-07-08 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
AU755564B2 (en) | 1998-06-20 | 2002-12-12 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
CA2351739A1 (en) | 1998-08-28 | 2000-03-09 | Gryphon Sciences | Polyamide chains of precise length, methods to manufacture them and their conjugates with proteins |
JP2002525329A (ja) | 1998-09-25 | 2002-08-13 | セフアロン・インコーポレーテツド | 感覚毛細胞及び蝸牛ニューロンへの損傷を予防する/処置するための方法 |
US6656474B1 (en) | 1999-01-15 | 2003-12-02 | Regeneron Pharmaceuticals, Inc. | Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders |
US6673908B1 (en) | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
JP2003506071A (ja) | 1999-05-28 | 2003-02-18 | アポプトシス テクノロジー,アイエヌシー. | アポトーシスを制御する化合物および方法ならびにアポトーシスを制御する化合物を製造およびスクリーニングする方法 |
US7510824B2 (en) | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
WO2000075118A1 (en) | 1999-06-03 | 2000-12-14 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) |
WO2000075164A1 (en) | 1999-06-07 | 2000-12-14 | Mirus Corporation | COMPOSITIONS AND METHODS FOR DRUG DELIVERY USING pH SENSITIVE MOLECULES |
MXPA02001857A (es) | 1999-08-24 | 2003-07-14 | Cellgate Inc | Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales. |
US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
EP1210362A2 (en) | 1999-09-01 | 2002-06-05 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, dna and viruses |
US20030104622A1 (en) | 1999-09-01 | 2003-06-05 | Robbins Paul D. | Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses |
US20030108539A1 (en) | 2000-02-14 | 2003-06-12 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US6610820B1 (en) * | 1999-10-12 | 2003-08-26 | University Of Lausanne | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US8183339B1 (en) | 1999-10-12 | 2012-05-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US20040082509A1 (en) | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
CN100475953C (zh) | 1999-12-06 | 2009-04-08 | 通用医疗公司 | 胰腺干细胞 |
US6586403B1 (en) | 2000-07-20 | 2003-07-01 | Salpep Biotechnology, Inc. | Treating allergic reactions and inflammatory responses with tri-and dipeptides |
US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
US6960648B2 (en) | 2000-10-13 | 2005-11-01 | Universite De Lausanne | Intracellular delivery of biological effectors |
US7033597B2 (en) | 2000-10-13 | 2006-04-25 | Université de Lausanne | Intracellular delivery of biological effectors |
AU2002211122B2 (en) | 2000-10-17 | 2005-06-23 | Diatranz Otsuka Limited | Preparation and xenotransplantation or porcine islets |
US7199124B2 (en) | 2001-02-02 | 2007-04-03 | Takeda Pharmaceutical Company Limited | JNK inhibitor |
US20030077826A1 (en) | 2001-02-02 | 2003-04-24 | Lena Edelman | Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC) |
US20030091640A1 (en) | 2001-02-08 | 2003-05-15 | Srinivasan Ramanathan | Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents |
JP2005508832A (ja) | 2001-02-16 | 2005-04-07 | セルゲイト, インコーポレイテッド | 間隔を開けてアルギニン部分を含むトランスポーター |
DE10117281A1 (de) | 2001-04-06 | 2002-10-24 | Inst Molekulare Biotechnologie | Peptid zur Diagnose und Therapie der Alzheimer-Demenz |
ATE343591T1 (de) | 2001-04-06 | 2006-11-15 | Univ Jefferson | Antagonist für die multimerisierung von hiv-1 vif-protein |
WO2003008553A2 (en) | 2001-07-17 | 2003-01-30 | Incyte Genomics, Inc. | Proteins associated with cell growth, differentiation, and death |
AU2002337142B2 (en) | 2001-09-19 | 2007-10-11 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
CA2471762C (en) | 2002-01-09 | 2010-08-17 | University Of Lausanne | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
NZ535349A (en) | 2002-03-08 | 2007-01-26 | Signal Pharm Inc | JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular |
SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
CA2496400A1 (en) | 2002-09-09 | 2004-03-18 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
CN1684738A (zh) | 2002-09-20 | 2005-10-19 | 爱尔康公司 | 细胞因子合成抑制剂用于治疗干眼病的用途 |
ATE350480T1 (de) | 2002-10-11 | 2007-01-15 | Imvision Gmbh | Moduläre antigen-transporter moleküle (mat- moleküle) zur modulierung von immunreaktionen, zugehörige konstrukte, verfahren und verwendungen |
WO2004037196A2 (en) | 2002-10-24 | 2004-05-06 | Sangstat Medical Corporation | Cytomodulating peptides and methods for treating neurological disorders |
CA2505479A1 (en) | 2002-11-14 | 2004-06-03 | Arbor Vita Corporation | Molecular interactions in neurons |
US20040167199A1 (en) | 2002-11-18 | 2004-08-26 | Celgene Corporation | Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
US20050019366A1 (en) | 2002-12-31 | 2005-01-27 | Zeldis Jerome B. | Drug-coated stents and methods of use therefor |
US7166692B2 (en) | 2003-03-04 | 2007-01-23 | Canbrex Bio Science Walkersville, Inc. | Intracellular delivery of small molecules, proteins, and nucleic acids |
EP2295433A3 (en) | 2003-03-06 | 2011-07-06 | Eisai R&D Management Co., Ltd. | JNK inhibitors |
US20080090770A1 (en) | 2003-04-11 | 2008-04-17 | Belmares Michael P | Modulation of Muc1 Mediated Signal Transduction |
ES2500921T3 (es) | 2003-04-29 | 2014-10-01 | Sarepta Therapeutics, Inc. | Composiciones para potenciar el transporte y la eficacia antisentido de análogos de ácidos nucleicos en células |
AU2004316996A1 (en) | 2003-06-20 | 2005-09-15 | The Regents Of The University Of California | Polypeptide transduction and fusogenic peptides |
KR100685345B1 (ko) | 2004-03-27 | 2007-02-22 | 학교법인조선대학교 | 세포사 유도 펩타이드 |
UA91676C2 (ru) | 2004-04-08 | 2010-08-25 | Эплайд Рисерч Системз Эрс Холдинг Н.В. | Композиция, которая содержит ингибитор jnk и циклоспорин |
WO2006021458A2 (en) | 2004-08-27 | 2006-03-02 | Gpc Biotech Ag | Pyrimidine derivatives |
US20060094753A1 (en) | 2004-10-29 | 2006-05-04 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases |
EP1656951A1 (en) | 2004-11-12 | 2006-05-17 | Xigen S.A. | Conjugates with enhanced cell uptake activity |
EP1676574A3 (en) | 2004-12-30 | 2006-07-26 | Johnson & Johnson Vision Care, Inc. | Methods for promoting survival of transplanted tissues and cells |
US20060223807A1 (en) | 2005-03-29 | 2006-10-05 | University Of Massachusetts Medical School, A Massachusetts Corporation | Therapeutic methods for type I diabetes |
US20070015779A1 (en) | 2005-04-29 | 2007-01-18 | John Griffin | Compositions and treatments for inhibiting kinase and/or hmg-coa reductase |
JP2008540345A (ja) | 2005-04-29 | 2008-11-20 | セルジーン・コーポレーション | 1−(5−(1h−1,2,4−トリアゾール−5−イル)(1h−インダゾール−3−イル))−3−(2−ピペリジルエトキシ)ベンゼンの固体形態 |
US20070003531A1 (en) | 2005-06-30 | 2007-01-04 | University Of Connecticut | Methods for improving immunotherapy by enhancing survival of antigen-specific cytotoxic T lymphocytes |
WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
US8080517B2 (en) | 2005-09-12 | 2011-12-20 | Xigen Sa | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US10045953B2 (en) | 2006-07-06 | 2018-08-14 | Case Western Reserve University | Ceramide composition and method of use |
WO2008094208A2 (en) | 2006-08-02 | 2008-08-07 | Northwestern University | Protein kinase targeted therapeutics |
CN101511359B (zh) | 2006-09-08 | 2012-09-05 | 霍夫曼-拉罗奇有限公司 | 苯并三唑激酶调节剂 |
CA2663545A1 (en) * | 2006-09-19 | 2008-03-27 | Phylogica Limited | Neuroprotective peptide inhibitors of ap-1 signaling and uses thereof |
GB0702259D0 (en) | 2007-02-06 | 2007-03-14 | Eisai London Res Lab Ltd | 7-azaindole derivatives |
ES2530723T3 (es) | 2008-05-07 | 2015-03-04 | Univ California | Reposición y enriquecimiento terapéuticos de la lubricación de la superficie ocular |
WO2009143864A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
WO2009143865A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2010065850A2 (en) | 2008-12-04 | 2010-06-10 | University Of Massachusetts | Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition |
WO2010113753A1 (ja) | 2009-03-30 | 2010-10-07 | 参天製薬株式会社 | JNK(c-Junアミノ末端キナーゼ)阻害ペプチドを用いた網膜疾患の予防または治療剤、網膜疾患の予防または治療方法、ならびに、その使用 |
WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
DK2902035T3 (en) | 2010-10-14 | 2018-09-24 | Xigen Inflammation Ltd | METHODS FOR TREATING MUSCLE DYROPHY |
US9150618B2 (en) | 2010-10-14 | 2015-10-06 | Xigen Inflammation Ltd. | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
US8471027B2 (en) | 2011-04-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Adamantyl compounds |
WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
WO2014206426A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
-
2005
- 2005-09-12 WO PCT/EP2005/009782 patent/WO2007031098A1/en active Application Filing
-
2006
- 2006-09-12 BR BRPI0616824A patent/BRPI0616824B8/pt active IP Right Grant
- 2006-09-12 ZA ZA200800848A patent/ZA200800848B/xx unknown
- 2006-09-12 JP JP2008530405A patent/JP5386169B2/ja active Active
- 2006-09-12 RS RS20120310A patent/RS52379B/en unknown
- 2006-09-12 PT PT06792004T patent/PT1928903E/pt unknown
- 2006-09-12 DK DK11003985.6T patent/DK2418217T3/en active
- 2006-09-12 ME MEP-2014-123A patent/ME02000B/me unknown
- 2006-09-12 EP EP06792004A patent/EP1928903B1/en active Active
- 2006-09-12 US US12/066,657 patent/US8748395B2/en active Active
- 2006-09-12 EP EP11003985.6A patent/EP2418217B1/en active Active
- 2006-09-12 RS RS20160222A patent/RS54701B1/en unknown
- 2006-09-12 WO PCT/EP2006/008882 patent/WO2007031280A2/en active Application Filing
- 2006-09-12 DK DK06792004.1T patent/DK1928903T3/da active
- 2006-09-12 KR KR1020087006094A patent/KR101305533B1/ko active IP Right Grant
- 2006-09-12 PL PL11003985T patent/PL2418217T4/pl unknown
- 2006-09-12 PL PL06792004T patent/PL1928903T3/pl unknown
- 2006-09-12 HU HUE11003985A patent/HUE029132T2/en unknown
- 2006-09-12 UA UAA200804223A patent/UA98101C2/ru unknown
- 2006-09-12 ES ES06792004T patent/ES2388076T3/es active Active
- 2006-09-12 SI SI200632044A patent/SI2418217T1/sl unknown
- 2006-09-12 SI SI200631345T patent/SI1928903T1/sl unknown
- 2006-09-12 CN CN2006800333412A patent/CN101263157B/zh active Active
- 2006-09-12 EP EP15002528.6A patent/EP3012266A1/en not_active Withdrawn
- 2006-09-12 CA CA2621337A patent/CA2621337C/en active Active
- 2006-09-12 EA EA200800680A patent/EA014330B1/ru not_active IP Right Cessation
- 2006-09-12 AU AU2006291541A patent/AU2006291541B2/en active Active
- 2006-09-12 ME MEP-2016-62A patent/ME02426B/me unknown
- 2006-09-12 ES ES11003985.6T patent/ES2567708T3/es active Active
-
2008
- 2008-01-30 IL IL189133A patent/IL189133A/en active IP Right Grant
- 2008-04-04 NO NO20081664A patent/NO342272B1/no not_active IP Right Cessation
- 2008-11-26 HK HK08112945.3A patent/HK1118841A1/xx unknown
-
2012
- 2012-01-05 JP JP2012000381A patent/JP5727393B2/ja active Active
- 2012-05-08 HK HK12104474.3A patent/HK1163712A1/zh unknown
- 2012-07-04 CY CY20121100593T patent/CY1112924T1/el unknown
- 2012-07-19 HR HRP20120598TT patent/HRP20120598T1/hr unknown
-
2013
- 2013-12-31 US US14/144,938 patent/US9290538B2/en active Active
-
2014
- 2014-10-23 JP JP2014216270A patent/JP2015034171A/ja not_active Withdrawn
-
2015
- 2015-03-26 IL IL237984A patent/IL237984A0/en unknown
-
2016
- 2016-02-16 US US15/045,058 patent/US20160264630A1/en not_active Abandoned
- 2016-04-11 CY CY20161100290T patent/CY1117351T1/el unknown
- 2016-04-12 HR HRP20160379TT patent/HRP20160379T1/hr unknown
- 2016-10-24 HK HK16112196.9A patent/HK1223948A1/zh unknown
-
2017
- 2017-06-21 US US15/628,771 patent/US20170320917A1/en not_active Abandoned
-
2019
- 2019-07-29 US US16/525,234 patent/US20200062805A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1112924T1 (el) | Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγης | |
CY1122691T1 (el) | Πρωτεϊνες δεσμευσης αλβουμινης ορου | |
CY1122800T1 (el) | Συνθεσεις του παραγοντα viii και μεθοδοι δημιουργιας και χρησης αυτων | |
CY1121687T1 (el) | Αλληλουχιες αμινοξεων που κατευθυνονται εναντι των πρωτεϊνων φακελου ενος ioy και πολυπεπτιδια που τις περιεχουν για τη θεραπευτικη αντιμετωπιση ιικων νoσων | |
MY167231A (en) | Amino acid sequences directed against IL-17A, IL-17F and/or IL17-A/F and polypeptides comprising the same | |
CY1120789T1 (el) | Προϊοντα γονιδιων εκφραζομενα διαφορικα μεσα σε ογκους και εφαρμογη αυτων | |
EA201001883A1 (ru) | Мутанты fgf21 и их применение | |
EA201171220A1 (ru) | Мутанты fgf21 и их применение | |
EA201891127A1 (ru) | Нуклеиновые кислоты, кодирующие повторяющиеся аминокислотные последовательности с высоким содержанием пролиновых и аланиновых остатков, имеющие нуклеотидные последовательности с низкой повторяемостью | |
CY1113713T1 (el) | Ανοσοκατασταλτικα πολυπεπτιδια και νουκλεϊκα οξεα | |
CA2818969A1 (en) | Improved n-terminal capping modules for designed ankyrin repeat proteins | |
PH12019500209A1 (en) | Methods and compositions for gene expression in plants | |
MX2010005783A (es) | Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas. | |
EA201100070A1 (ru) | Туберкулезный белок rv2386c, композиции и их применения | |
CY1118012T1 (el) | Συνθεσεις αναστολεων κινασης και η χρηση αυτων για την αγωγη καρκινου και αλλων νοσηματων σχετικων προς τις κινασες | |
MX2014006399A (es) | Uso de inhibidores de peptidos con celulas permeables de la via para transduccion de señal de jnk para el tratamiento de la queratoconjuntivitis seca. | |
MX2019003298A (es) | Proteinas de union recombinantes y sus usos. | |
DK1888640T3 (da) | Forbedrede nanobodies mod tumornekrosefaktor-alfa | |
ATE541283T1 (de) | Verfahren zum mischen von farben in einem display | |
MX2016017308A (es) | Nuevo uso de inhibidores de peptido permeables a celulas de la ruta de transduccion de señal jnk para el tratamiento de varias enfermedades. | |
MX2009009598A (es) | Reovirus que tienen secuencias modificadas. | |
IL173952A0 (en) | Anti-angiogenic peptides and pharmaceutical compositions based thereon | |
CY1114747T1 (el) | Χιμαιρα dna πολυμερασης φαγου φ 29 | |
EA201100071A1 (ru) | Новые композиции и способы | |
CY1114075T1 (el) | Ενωσεις αλφα κετοαμιδιου ως αναστολεις πρωτεασης κυστεϊνης |